Optic nerve repair could treat glaucoma:
This article was originally published in Clinica
Executive Summary
Mice treated with Boston Life Sciences' central nervous system growth factor Axogenesis Factor 1 (AF1) have re-grown severed axons within the optic nerve, suggesting that AF1 could be used to treat blindness caused by glaucoma. Degenerative injury to the optic nerve destroys the vision of glaucoma sufferers. This is the first time that injection of a single nerve growth factor has resulted in optic nerve regeneration, says Boston Life Sciences. The company's chief scientific officer, Dr Marc Lanser said, "These exciting data suggest that AF1 has the potential to be a totally novel approach to the treatment of glaucoma."
You may also be interested in...
‘Parity To The Originator Is Not Enough’ – Cardinal Health Talks US Biosimilars
Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.